I n 2014, there were about 18,860 new cases of adult acute myeloid leukemia (AML) and 10,460 deaths from the disease in the United States, which is more than any other type of leukemia. 1 It is the sixth most common cancer in men and women. 1 Terapeutic advances in AML have resulted in improved complete remission (CR) rates; 1 however, there are still a number of aspects of this disease for which evidence-based guidelines are lacking, such as induction therapy in older patients as well as postremission therapy in all patients. 2 It is important to have an understanding of short-and long-term outcomes of treatment regimens because most of these therapies have serious, often debilitating adverse efects. Hence, individualizing therapy in patients using a risk-beneft model would help in choosing appropriate regimens. Emerging data has identifed various cytogenetics and somatic mutations with prognostic value in AML. Tis has broadened our understanding of the disease, in particular its heterogeneity; however, the impact of most of these genetic and molecular mutations on clinical practice remains unclear. 3 Tere is still a need for development of an accurate and personalized risk prediction model for patients to individualize therapies, especially in the elderly population.
Chemotherapy with a cytarabine plus anthracycline (doxorubicin or daunorubicin) combination (7+3 regimen) has resulted in a CR rate of between 50%-70% in AML patients younger than 60 years, although rates are variable for elderly patients. [4] [5] [6] [7] CR is commonly defned as bone marrow blast count of ≤5% with recovery of all the 3 cell lines in the peripheral blood. CR with incomplete count recovery, defned as no evidence of persistent disease but an incomplete recovery of blood counts, occurs frequently and is associated with a worse prognosis compared with patients with normal count recovery. In contrast, a small percentage of patients have an increased platelet count at the end of the month after initiation of induction chemotherapy, and the clinical signifcance of this has yet to be investigated. Our hypothesis was that CR increased platelet count at day 30 translated to a superior survival rate compared with CR with subnormal or normal platelet counts because of a potentially rapid recovery of the bone marrow after induction chemotherapy.
Materials and methods
A total of 104 patients diagnosed with AML were considered from the leukemia database registry of Georgia Regents University. Institutional review board approval was obtained prior to reviewing records. Adult AML patients (≥18 years) who survived at least 30 days after initiation of Figure 3) . b Culture-proven infections in relation to the frst cycle of induction chemotherapy. Original Report frst cycle of induction chemotherapy with the cytarabine plus anthracycline (doxorubicin or daunorubicin) combination, or 7+3 regimen, were included in the analysis. Untreated patients (n = 18) and patients who underwent platelet transfusions during days 25-35 after the frst cycle of induction were excluded.
Patient characteristics such as age; sex; race; risk category based on cytogenetics/mutation analysis as per the European LeukemiaNet recommendations 8 ( Figure 3 ); culture-proven infections (≤1 month before, during, and ≤6 months after induction therapy); remission status (bone marrow blast cell percentage of ≤5) at day 30 (bone marrow biopsy results were considered during days 25-35 after frst cycle of induction chemotherapy); and whether allogeneic stem-cell transplantation (SCT) was performed or not, were recorded (Table 1 ). In addition, platelet count at day 0 (day of initiation of frst cycle of induction chemotherapy); highest platelet count during days 25-35 (designated as day 30 platelet count); day 14+ plasma cell count (average plasma cell percentage at days 14-21).
Overall survival (OS) was noted and survival estimates were calculated using Kaplan-Meir analysis. Patients from the complete remission group were divided into 3 groups: platelet count <50,000/mcL (n = 17), 51,000-400,000/mcL (n = 72), and >400,000/mcL (n = 15); and their survival curves were compared ( Figure 1 ). Survival was also stratifed for age, sex, race, and risk (Figures 2, 3) . A multivariate analysis was conducted for the following factors: age; sex; culture-proven infections, allogeneic SCT performed or not; day 30 platelet count; day 14+ plasma cell count; and induction chemotherapy considered or not ( Table  2) . Statistical analysis was done using Statistical Analysis Software (SAS edition 9.4).
Results
Mean follow-up period for the study was 168 months, and mean survival was 42 months. Mean age of the patients was 55.8 years. Age was grouped into 3 ranges: <55 years (n = 43); 56-75 years (n = 53); and >75 years (n = 8). KaplanMeir survival analysis was signifcant for higher survival in the <55-year age group, followed by the 56-75-year group and then the >75-year group (Figure 2 , P = .0005). Sex distribution was fairly even, with 54 men and 50 women participating. No signifcant diference in OS was found between the sexes (P = .839). Te majority of the patients were white (n = 65), followed by African-American (n = 35), and Hispanic (n = 3); 1 patient's race could not be ascertained from the records. No racial diferences in survival were apparent (P = .287). Based on the European LeukemiaNet's recommended risk categories, the favorable risk group had 13 patients; the intermediate and adverse risk groups had 59 and 21 patients, respectively; and 11 patients could not be categorized from records. As expected, OS was highest in the favorable group, followed by intermediate and poor risk groups respectively (P = .0014, Figure 3 ). Tis diference was also highlighted in the multivariate analysis with poor risk category showing a higher odds ratio of 4.99 (95% confdence index [CI], 1.53, 16.32; P = .008). Of the 104 patients, 63 achieved CR, defned as reduction in bone marrow blast cells to ≤5% after frst induction cycle at the end of 1 month after diagnosis; 30 did not achieve CR; and status could not be ascertained from the records for 11 patients. In all, 16 of 104 patients underwent an allogeneic SCT. Te average day 30 platelet count in the group receiving SCT was 216,000/ mcL and average OS was 745 days. As expected, allogeneic SCT had a strong efect on OS, with patients who did not undergo it having an odds ratio of 8.7 (95% CI, 2.36, 32.07; P = .0007).
Infections ≤1 month before and during the frst cycle of induction were not signifcant prognostic indicators of OS. Of the 104 patients, 24 had culture-proven infection during induction chemotherapy (group 1), 22 had infection ≤6 months after induction chemotherapy (group 2), and 58 either had infections ≤6 months before or had no infections recorded during those time frames (group 3). In group 1, average day 30 platelet count was 186/mcL and OS was 524 days; in group 2, the numbers were 251/mcL and 395 days, respectively; and in group 3, they were 244/mcL and 537 days, respectively. Tis data suggests that infections were likely not responsible for upregulating platelet production. In addition, there was not a strong correlation between day 0 platelet count (platelet count at diagnosis and before the start of frst cycle of induction chemotherapy) and day 0 platelet count (r = 0.1891, P = .033). Kaplan-Meir survival curves for the diferent platelet groups showed statistical signifcance using the log-rank test (P = .005). Tis diference remained signifcant (P = .012) after performing a multivariate analysis using the Cox Proportional Hazards Model. Tere was a similar trend in the CR group, (P = .061, log-rank test, Figure 2) . Furthermore, on multivariate analysis, the >400,000/mcL platelet group showed a signifcant lower odds ratio compared with the other groups (0.22; 95% CI, 0.06, 0.83; P = .026), indicating a better OS. Of the 104 patients, 28 underwent relapse after the frst induction cycle, 25 stayed in remission, and the status of 51 patients could not be reliably ascertained from the medical records. A similar trend was observed in the relapse-free survival among the platelet survival groups (354.6 days for the <50,000/mcL group (n = 5); 372 days for the 50,000-400,000/mcL group (n = 34), and 805.07 days (n = 14) for the >400,000/mcL group), see Table 2 .
Discussion
Complete remission in acute myeloid leukemia is defned as having a blast count of ≤5% in a bone marrow peripheral smear, platelet (>100,000/mcL) and neutrophil recovery (>1.0x10 9 /mcL) and no extramedullary involvement. In HOVON-SAKK co-operative group studies, the median time to remission was about 32 days. 9 However, a small subset of patients with blast counts of ≤5% but incomplete platelet recovery at the end of 1 month of induction therapy showed poor outcomes. 10 Tis exclusive subset, known as CR with incomplete platelet recovery, fulflled all the criteria of remission except that platelet counts were less than 100,000/mcL, provided that patients were not depen- The highest platelet count during days 25-35 from initiation of induction chemotherapy was designated as day 30 platelet count.
d Day 14+ plasma cell count is the average plasma cell percentage at days 14-21.
e Based on cytogenetics/molecular analysis as per the European LeukemiaNet recommendations 8 (see Figure 3 ).
Original Report dent on platelet transfusions. On the one hand, although CR with incomplete platelet recovery shows poor outcomes when compared with CR, it is a distinct subcategory in itself and shows a clinically meaningful response to drugs as it correlates with better outcomes when compared with resistant disease. 10 On the other hand, there is another small subset of patients who achieve CR with blasts count ≤5% and who have much higher platelet counts (>400,000/ mcL). Our data suggests that the latter have better outcomes than those with CR with incomplete or normal platelet recovery. We theorize that an increased platelet count at the end of 1 month after initiation of induction chemotherapy is indicative of a more robust bone marrow recovery and response to induction chemotherapy, and this translates to an increased survival. Te mechanism certainly needs to be further elucidated.
Bolwell and colleagues assessed the prognostic importance of day 100 platelet count after allogeneic SCT in patients with AML. Tey looked at 107 patients who survived at least 100 days following an ablative allogeneic SCT and found the higher platelet count to be a strong predictor of OS.
11 Al-Shugair and colleagues reported that day 14+ plasma cells in the bone marrow aspirates after induction chemotherapy correlated positively with the presence of residual leukemic blast cells, although they found no correlation with OS. 12 Te mechanism for this trend was thought to be secondary to an increased interleukin-6 (IL-6) secretion from leukemic blast cells stimulating plasma cell production. Antecedent infections and/ or other infammatory processes are postulated to increase plasma cell production. Also, they found higher plasma cell counts in patients with antecedent or concurrent infection and/or infammation compared with those without (18.1 vs 10.7%, P = .039). 12 It is debatable at this time whether the same translates for platelet counts. In our multivariate analysis, we did not fnd day 14+ plasma cell count to be an independent predictor of survival.
Several prognostic factors have been identifed for patients with AML. Historically, age was recognized as one of the most important prognostic factors. It is well known that older age group is associated with adverse outcomes because of poorer performance status and unfavorable cytogenetics. 13 Our data are consistent with this and show an adverse prognosis with increasing age (Figure 2) . AML is known to be a clinically heterogeneous disease and blast cell morphology is another important determinant of prognosis.
14 Cytogenetics remains the most important prognostic factor, with the disease characterized as favorable, intermediate, or poor risk. 12, [14] [15] [16] [17] Our data was consistent with the established risk factors, with OS showing the expected trend in each of these groups (P = .0014).
Another potential confounding factor afecting day 30 platelet count is infections. Infections have been postulated to cause IL-6 upregulation and stimulation of thrombopoeitin production in the liver, which can facilitate platelet production. 17, 18 We evaluated for an occurrence of infections ≤1 month before, during, and ≤6 months after induction chemotherapy. Te group with infections during induction chemotherapy had lower average platelet counts, suggesting that infections likely did not falsely upregulate platelet counts. Infections during induction chemotherapy (days 0-30) was not a statistically signifcant independent predictor of survival in our analysis (OR, 1.89; 95% CI, 0.75-4.76; P = .178).
Future research should include studies to elucidate underlying molecular pathophysiology to identify novel therapeutic targets. Subcategorizing CR to incomplete, complete, and superior platelet recovery may help in better delineation of efcacy of future investigational agents.
In conclusion, CR with superior platelet count is a unique subcategory in itself and should be further categorized into CR with incomplete, normal, and superior platelet count to better characterize response to induction chemotherapy.
